Development and clinical use of CAMPATH® 1H

Transplantation Reviews

Volumn 17, Issue 4 SUPPL., 2003, Pages

  Waldmann, Herman ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; CD4 ANTIGEN; CYCLOSPORIN; FLUDARABINE; IMMUNOGLOBULIN G2B; INTERLEUKIN 2 RECEPTOR; METHOTREXATE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CHRONIC LYMPHATIC LEUKEMIA; DRUG APPROVAL; DRUG EFFICACY; DRUG SYNTHESIS; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; MAINTENANCE THERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; ORGAN TRANSPLANTATION; T LYMPHOCYTE ACTIVATION;

EID: 0344237261     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2003.07.009     Document Type: Article

References (13)

1. Waldmann H, Polliak A, Hale G, et al: Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984, 2:483
2. Dyer MJS, Hale G, Hayhoe FGJ, et al: Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype. Blood 1989, 73:1431
3. Hale G, Waldmann H: Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant 1994, 13:597
4. Hale G, Zhang MJ, Bunjes D, et al: Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998, 92:4581
5. Riechmann L, Clark M, Waldmann H, et al: Reshaping human antibodies for therapy. Nature 1988, 332:323
6. Hale G, Dyer MJ, Clark MR, et al: Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988, 2:1394
7. Isaacs JD, Watts RA, Hazleman BL, et al: Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992, 340:748
8. Lockwood CM, Thiru S, Isaacs JD, et al: Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 1993, 341:1620
9. Moreau T, Thorpe J, Miller D, et al: Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis [published erratum appears in Lancet 1994, 344:486]. Lancet 1994, 344:298
10. Lockwood CM, Thiru S, Stewart S, et al: Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJ Med 1996, 89:903
11. Isaacs,JD, Hazleman BL, Chakravarty K, et al: Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H. J Rheumatol 1996, 23:1103
12. Lundin J, Kimby E, Bjorkholm M, et al: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002, 100:768
13. Calne R, Moffatt SD, Friend PJ, et al: Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999, 68:1613